21.07
前日終値:
$21.51
開ける:
$21.57
24時間の取引高:
192.19K
Relative Volume:
0.87
時価総額:
$1.05B
収益:
-
当期純損益:
$-85.21M
株価収益率:
-11.15
EPS:
-1.89
ネットキャッシュフロー:
$-68.53M
1週間 パフォーマンス:
-0.05%
1か月 パフォーマンス:
+4.57%
6か月 パフォーマンス:
-12.68%
1年 パフォーマンス:
+19.78%
Enliven Therapeutics Inc Stock (ELVN) Company Profile
ELVN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ELVN
Enliven Therapeutics Inc
|
21.07 | 1.05B | 0 | -85.21M | -68.53M | -1.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-13 | 開始されました | BTIG Research | Buy |
2024-09-09 | 開始されました | H.C. Wainwright | Buy |
2024-06-11 | 開始されました | Robert W. Baird | Outperform |
2024-04-09 | 開始されました | Mizuho | Buy |
2023-03-29 | 開始されました | Jefferies | Buy |
Enliven Therapeutics Inc (ELVN) 最新ニュース
Enliven Therapeutics CFO sells $22,504 in stock By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO sells $22,504 in stock - Investing.com India
Charles Schwab Investment Management Inc. Grows Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Bank of New York Mellon Corp Sells 828 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics chief scientific officer sells $257,575 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics chief scientific officer sells $257,575 in stock - Investing.com India
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory - Marketscreener.com
(ELVN) Technical Pivots with Risk Controls - Stock Traders Daily
Lifesci Capital Issues Optimistic Forecast for ELVN Earnings - Defense World
Enliven Therapeutics CEO Samuel Kintz sells $260,320 in stock - Investing.com
Enliven Therapeutics CEO Samuel Kintz sells $260,320 in stock By Investing.com - Investing.com UK
Decoding Enliven Therapeutics Inc (ELVN): A Strategic SWOT Insig - GuruFocus.com
Enliven grew fourth-quarter R&D spending with trials underway - BizWest
Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline - Value the Markets
Enliven Therapeutics Reports 2024 Financial Results - TipRanks
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - Citizentribune
Enliven Therapeutics Inc. (ELVN) reports earnings - Quartz
Enliven Therapeutics Q4 Operating Expenses USD 26.896 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
ENLIVEN THERAPEUTICS Earnings Results: $ELVN Reports Quarterly Earnings - Nasdaq
Enliven Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (ELVN) Enliven Therapeutics Posts Q4 Loss $-0.46 Per Share -March 13, 2025 at 04:12 pm EDT - Marketscreener.com
Enliven Therapeutics COO Anish Patel sells $142,936 in stock - Investing.com
Enliven Therapeutics COO Anish Patel sells $142,936 in stock By Investing.com - Investing.com Australia
(ELVN) Investment Analysis and Advice - Stock Traders Daily
Enliven Therapeutics (ELVN) Projected to Post Quarterly Earnings on Thursday - Defense World
New York State Common Retirement Fund Sells 2,488 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics CFO Sells Shares - TradingView
Enliven Therapeutics CFO sells $22,524 in stock - MSN
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Longview News-Journal
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference – Company Announcement - Financial Times
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap DownHere's Why - MarketBeat
(ELVN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $146,207.31 in Stock - MarketBeat
Enliven Therapeutics COO Anish Patel sells $146,205 in stock - MSN
Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat
Enliven Therapeutics COO Anish Patel sells $146,205 in stock By Investing.com - Investing.com South Africa
Trend Tracker for (ELVN) - Stock Traders Daily
Enliven Therapeutics: Promising Innovations in Tyrosine Kinase Inhibitors and Strategic Growth Plans Justify Buy Rating - TipRanks
SG Americas Securities LLC Increases Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Strong Buy Recommendation for Enliven Therapeutics Due to ELVN-001’s High Selectivity and Promising Clinical Data - TipRanks
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares - MarketBeat
Enliven Therapeutics CFO sells $70,177 in stock - MSN
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Enliven Therapeutics Inc (ELVN) 財務データ
収益
当期純利益
現金流量
EPS
Enliven Therapeutics Inc (ELVN) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Mar 24 '25 |
Option Exercise |
2.48 |
1,000 |
2,480 |
24,000 |
Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Mar 24 '25 |
Sale |
22.50 |
1,000 |
22,504 |
23,000 |
Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER |
Mar 19 '25 |
Sale |
20.61 |
12,500 |
257,575 |
1,002,688 |
Kintz Samuel | PRESIDENT AND CEO |
Mar 17 '25 |
Sale |
20.83 |
12,500 |
260,320 |
990,392 |
大文字化:
|
ボリューム (24 時間):